Patents by Inventor Joseph Zimmermann
Joseph Zimmermann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11952285Abstract: A process of forming a sintered article includes heating a green portion of a tape of polycrystalline ceramic and/or minerals in organic binder at a binder removal zone to a temperature sufficient to pyrolyze the binder; horizontally conveying the portion of tape with organic binder removed from the binder removal zone to a sintering zone; and sintering polycrystalline ceramic and/or minerals of the portion of tape at the sintering zone, wherein the tape simultaneously extends through the removal and sintering zones.Type: GrantFiled: July 25, 2023Date of Patent: April 9, 2024Assignee: Corning IncorporatedInventors: Micheal Edward Badding, William Joseph Bouton, Douglas Edward Brackley, Lanrik Wayne Kester, Thomas Dale Ketcham, Eric Lee Miller, Cameron Wayne Tanner, James William Zimmermann
-
Publication number: 20070264176Abstract: The present invention relates to a process and apparatus for the production of light olefins comprising olefins having from 2 to 3 carbon atoms per molecule from a feedstock containing heavier olefins. An intermediate cut from a fractionation column is used as olefinic feed to an olefin cracking process preferably after undergoing selective hydrogenation of diolefins. In one embodiment, a liquid side draw from a fractionation column is selectively hydrogenated and then returned to the fractionation column from which a vapor side draw containing olefins is cracked in the olefin cracking reactor.Type: ApplicationFiled: July 26, 2007Publication date: November 15, 2007Inventors: Douglas Stewart, Joseph Zimmermann, Angelo Furfaro, Bipin Vora
-
Publication number: 20070129586Abstract: Processing scheme and arrangement for increasing the relative yield of light olefins involves integration of the cracking a heavy hydrocarbon feedstock to produce an effluent comprising a range of hydrocarbon products including C4-C7 olefins and the subsequent cracking at least a portion of the C4-C7 olefins to produce additional light olefins.Type: ApplicationFiled: December 2, 2005Publication date: June 7, 2007Inventors: Joseph Zimmermann, Charles Luebke, John Baker
-
Publication number: 20060140928Abstract: Heparinase enzymes can be used as a medical treatment to reduce localized inflammatory responses. Treatment of activated endothelium with heparinase inhibits leukocyte rolling, adhesion and extravasation. Most of the heparin and heparan sulfate on endothelial cell surfaces and in basement membranes is degraded by exposure to heparinase. In addition, immobilized chemokines, which are attached to heparin/heparan sulfate on activated endothelium are solubilized by heparinase digestion. Heparinase can be infused into the vascular system to inhibit accumulation of leukocytes in inflamed tissue and decrease damage resulting from localized inflammations. Targeting of heparinase to activated endothelium can be accomplished through localized administration and/or use of genetically engineered heparinase containing endothelium ligand-binding domains.Type: ApplicationFiled: February 22, 2006Publication date: June 29, 2006Applicant: Biomarin Pharmaceutical Inc.Inventors: D. Bennett, Elizabeth Cauchon, Dominique Fink, Brigette Grouix, Ariane Hsia, Pamela Danagher, Joseph Zimmermann
-
Publication number: 20050191288Abstract: Heparinase enzymes can be used as a medical treatment to reduce localized inflammatory responses. Treatment of activated endothelium with heparinase inhibits leukocyte rolling, adhesion and extravasation. Most of the heparin and heparan sulfate on endothelial cell surfaces and in basement membranes is degraded by exposure to heparinase. In addition, immobilized chemokines, which are attached to heparin/heparan sulfate on activated endothelium are solubilized by heparinase digestion. Heparinase can be infused into the vascular system to inhibit accumulation of leukocytes in inflamed tissue and decrease damage resulting from localized inflammations. Targeting of heparinase to activated endothelium can be accomplished through localized administration and/or use of genetically engineered heparinase containing endothelium ligand-binding domains.Type: ApplicationFiled: May 2, 2005Publication date: September 1, 2005Applicant: Biomarin Pharmaceutical Inc.Inventors: D. Bennett, Elizabeth Cauchon, Dominique Fink, Brigette Grouix, Ariane Hsia, Pamela Danagher, Joseph Zimmermann
-
Publication number: 20010006635Abstract: Heparinase enzymes can be used as a medical treatment to reduce localized inflammatory responses. Treatment of activated endothelium with heparinase inhibits leukocyte rolling, adhesion and extravasation. Most of the heparin and heparan sulfate on endothelial cell surfaces and in basement membranes is degraded by exposure to heparinase. In addition, immobilized chemokines, which are attached to heparin/heparan sulfate on activated endothelium are solubilized by heparinase digestion. Heparinase can be infused into the vascular system to inhibit accumulation of leukocytes in inflamed tissue and decrease damage resulting from localized inflammations. Targeting of heparinase to activated endothelium can be accomplished through localized administration and/or use of genetically engineered heparinase containing endothelium ligand-binding domains.Type: ApplicationFiled: September 27, 1996Publication date: July 5, 2001Inventors: D. CLARK BENNETT, ELIZABETH CAUCHON, DOMINIQUE FINK, BRIGETTE GROUIX, ARIANE HSIA, PAMELA DANAGHER, JOSEPH ZIMMERMANN
-
Patent number: 6093563Abstract: The present invention describes a method for the production of two highly purified enzymes capable of degrading chondroitin sulfate polysaccharides. A multi-step purification method incorporating cell disruption, cation exchange chromatography, affinity chromatography, hydroxylapatite chromatography, high resolution ion exchange chromatography and size exclusion is outlined. A 77,000.+-.5,000 Dalton protein capable of degrading chondroitin sulfates A and C and a 55,000.+-.2,300 Dalton protein capable of degrading dermatan sulfate were isolated. The genes encoding these enzymes, chondroitinase AC and chondroitinase B, respectively, have been cloned and methods for their use are described.Type: GrantFiled: July 8, 1994Date of Patent: July 25, 2000Assignee: IBEX Technologies R and D, Inc.Inventors: D. Clark Bennett, Maryse Laliberte, Kangfu Gu, Joseph Zimmermann, Anna Lydia Tkalec, Dominique Fink, Robert Linhardt
-
Patent number: 6054569Abstract: The present invention describes a method for the production of two highly purified enzymes capable of degrading chondroitin sulfate polysaccharides. A multi-step purification method incorporating cell disruption, cation exchange chromatography, affinity chromatography, hydroxylapatite chromatography, high resolution ion exchange chromatography and size exclusion is outlined. A 77,000.+-.5,000 Dalton protein capable of degrading chondroitin sulfates A and C and a 55,000.+-.2,300 Dalton protein capable of degrading dermatan sulfate were isolated. The genes encoding these enzymes, chondroitinase AC and chondroitinase B, respectively, have been cloned and methods for their use are described.Type: GrantFiled: September 17, 1997Date of Patent: April 25, 2000Assignee: IBEX Technologies R and D, Inc.Inventors: D. Clark Bennett, Maryse Laliberte, Kangfu Gu, Joseph Zimmermann, Anna Lydia Tkalec, Dominique Fink, Robert Linhardt
-
Patent number: 5997863Abstract: Glycosaminoglycans, including heparinases 1, 2 and 3 as well as chondroitinases AC and B from the Gram negative bacteria Flavobacterium heparinum, can be used either separately or in combination to manipulate cell proliferation. In one embodiment, heparinases are administered to degrade heparan sulfate components of the extracellular matrix, thereby allowing the heparin binding growth factors which are stored in the extracellular matrix to migrate to adjacent cells. The mobility of chemoattractant agents, growth factors and cells also can be increased by treating tissues with glycosaminoglycan degrading enzymes, both chondroitinases and heparinases. The enzymatic removal of chondroitin sulfates from cell surfaces effectively increases the availability of growth factor receptors on the cell's surface. Selectively removing heparan sulfate from cell surfaces while leaving the extracellular matrix intact, conversely, inhibits cell proliferation by down regulating the cell's response to growth factors.Type: GrantFiled: July 8, 1994Date of Patent: December 7, 1999Assignee: Ibex Technologies R and D, Inc.Inventors: Joseph Zimmermann, Israel Vlodavsky, Clark Bennett, Pamela Danagher, Richard Broughton
-
Patent number: 5919693Abstract: The present invention describes the isolation and sequence of genes from Flavobacterium heparinum encoding heparin and heparan sulfate degrading enzymes, heparinase II and heparinase III (EC 4.2.2.8). It further describes a method of expressing and an expression for heparinases I, II and III using a modified ribosome binding region derived from a promoter from glycosaminoglycan lyase genes of F. heparinum. Also, a multi-step protein purification method incorporating cell disruption, cation exchange chromatography, affinity chromatography and hydroxylapatite chromatography is outlined. Antibodies against a post-translational modification moiety common to Flavobacterium heparinum proteins and a method to obtain antibodies specific to these moieties and to the amino acid sequences of heparinases I, II and III are described.Type: GrantFiled: July 25, 1997Date of Patent: July 6, 1999Assignee: IBEX Technologies Corp.Inventors: Hongsheng Su, Francoise Blain, Clark Bennett, Kangfu Gu, Joseph Zimmermann, Roy Musil
-
Patent number: 5681733Abstract: The present invention describes the isolation and sequence of genes from Flavobacterium heparinum encoding heparin and heparan sulfate degrading enzymes, heparinase II and heparinase III (EC 4.2.2.8). It further describes a method of expressing and an expression for heparinases I, II and III using a modified ribosome binding region derived from a promoter from glycosaminoglycan lyase genes of F. heparinum. Also, a multi-step protein purification method incorporating cell disruption, cation exchange chromatography, affinity chromatography and hydroxylapatite chromatography is outlined. Antibodies against a post-translational modification moiety common to Flavobacterium heparinum proteins and a method to obtain antibodies specific to these moieties and to the amino acid sequences of heparinases I, II and III are described.Type: GrantFiled: June 10, 1994Date of Patent: October 28, 1997Assignee: Ibex TechnologiesInventors: Hongsheng Su, Francoise Blain, Clark Bennett, Kangfu Gu, Joseph Zimmermann, Roy Musil